Neurocentrx Pharma

About Neurocentrx Pharma

Neurocentrx Pharma Ltd is a pharmaceutical company focused on developing innovative treatments for mental health disorders, specifically targeting depression. Their mission is to provide safe, accessible, and regulated ketamine-based care through their lead product, NRCx-201, aiming to improve the quality of life for individuals with severe mood disorders.

Products & Services

NRCx-201:An investigational drug-software combination product featuring an abuse-deterrent oral ketamine capsule and prescription safety software. It is designed for safe administration in clinical and home-care settings, targeting treatment-resistant major depressive disorder and bipolar II depression, with ongoing Phase 2 and Phase 3 trials.

Specialties

Oral Ketamine Therapy Mental Health Treatment Abuse-Deterrent Drug Development Digital Prescription Safety Tools

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed Extension T: - FT: Seed Extension	A: 5000000 MR: - FA: over $5 million FAN: 5000000	D: 2025-09-23 FD: 2025-09-23	1 investors

Seed Extension Latest

2025-09-23

$5.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

G

Graeme Duncan

Head of Clinical Development

R

Ronald Lindsay

Chairman and CEO

F

Fraser Lusty

Director

C

Clara Burtenshaw

Biotech and Life Sciences Investor

A

Allan Young

Professor

M

Metul Mehta

Professor of Neuroimaging & Psychopharmacology and Head of the Neuropharmacology Section

View 4 more team members with Pro

Unlock Full Team Directory

Recent News